Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia

Expert Opinion on Biological Therapy

Volumn 14, Issue 12, 2014, Pages 1837-1848

  Hashemi, Saba ^a   Ali Faramarzi, Mohammad ^a   Falavarjani, Khalil Ghasemi ^b   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Age related macular degeneration; Anti VEGF; Bevacizumab; Choroidal neovascularization; Pathological myopia; VEGF

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VERTEPORFIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

AGE RELATED MACULAR DEGENERATION; BLEEDING; BLOOD VESSEL OCCLUSION; CARDIOMYOPATHY; CENTRAL MACULAR THICKNESS; CENTRAL RETINAL THICKNESS; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG SAFETY; EARLY DIAGNOSIS; ENDOPHTHALMITIS; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; LOW LEVEL LASER THERAPY; MONOTHERAPY; MYOPIA; PHOTODYNAMIC THERAPY; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROTEINURIA; RETINA DETACHMENT; REVIEW; SUBRETINAL NEOVASCULARIZATION; THERAPY EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; IMMUNOLOGY; MACULAR DEGENERATION; MYOPIA, DEGENERATIVE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS, PHASE III AS TOPIC; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MYOPIA, DEGENERATIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84910036569     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.967210     Document Type: Review

References (80)

1. Gupta B, Elagouz M, Sivaprasad S. Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye (Lond) 2010;24:203-13
2. Cheung LK, Eaton A. Age-related macular degeneration. Pharmacotherapy 2013;33:838-55
3. Kato A, Yasukawa T, Ogura Y. Antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: search for the optimized treatment regimen. Taiwan J Ophthalmol 2014;4:3-8
4. Finger RP, Wickremasinghe SS, Baird PN, Guymer RH. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol 2014;59:1-18
5. Wang J, Kang Z. Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 2012;250:1717-23
6. Sayanagi K, Jo Y, Ikuno Y. Transient choroidal thinning after intravitreal bevacizumab injection for myopic choroidal neovascularization. J Clin Exp Ophthalmol 2011;2:165
7. Ikuno Y, Jo Y, Hamasaki T, Tano Y. Ocular risk factors for choroidal neovascularization in pathologic myopia. Invest Ophthalmol Vis Sci 2010;51:3721-5
8. Ng DS, Kwok AK, Chan CW. Anti-vascular endothelial growth factor for myopic choroidal neovascularization. Clin Exp Ophthalmol 2012;40:e98-e110
9. Wang E, Chen Y. Intravitreal antivascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 2013;33:1375-92
10. El-Mollayess GM, Noureddine BN, Bashshur ZF. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. Semin Ophthalmol 2011;26:69-76
11. Walia S, Varma P. Bevacizumab (Avastin) for ocular disorders. Int J Pharm Res 2013;3:59-68
12. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400
13. Issa PC, Chong NV, Scholl HP. The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application. Graefes Arch Clin Exp Ophthalmol 2011;249:163-74
14. Gohel PS, Mandava N, Olson JL, Durairaj PD. Age-related macular degeneration: an update on treatment. Am J Med 2008;121:279-81
15. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353-63 • This paper offers a comprehensive overview important because explain phathogenesis and treatments of agerelated macular degeneration (AMD).
16. Luthert PJ. Pathogenesis of age-related macular degeneration. Diagn Histopathol 2011;17:10-16
17. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48:257-93
18. Freund KB, Mrejen S, Gallego-Pinazo R. Current strategies for the management of treatment-resistant neovascular age-related macular degeneration. Curr Ophthalmol Rep 2014;2:6-13
19. Patel K, Chow C, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) 2013;27:663-8
20. Rush RB, Simunovic MP, Vandiver L, et al. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Retina 2013;34:846-52 • This Ref evaluating large number of patients with exudative AMD who treated with intravitreal bevacizumab.
21. Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol 2012;153:468-73
22. Axer-Siegel R, Bor E, Bourla DH, et al. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity. Retina 2012;32:1811-20
23. El-Mollayess GM, Mahfoud Z, Schakal AR, et al. Intravitreal Bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity. Retina 2013;33:1828-35
24. Leydolt C, Michels S, Prager F, et al. Effect of intravitreal bevacizumab (Avastin®) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol 2010;88:594-600
25. El-Mollayess GM, Mahfoud Z, Schakal AR, et al. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. Am J Ophthalmol 2012;153:481-9
26. Carneiro AM, Falcao MS, Brandao EM, Falcao-Reis FM. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Retina 2010;30:85-92
27. Alkin Z, Ozkaya A, Osmanbasoglu OA, et al. The role of epiretinal membrane on treatment of neovascular age-related macular degeneration with intravitreal bevacizumab. ScientificWorldJournal 2013;2013:958724
28. Jonas JB, Libondi T, Golubkina L, et al. Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. Acta Ophthalmol 2010;88:630-4
29. el Matri L, Chebil A, Kort F, et al. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2010;248:779-84
30. Yoshizawa C, Saito W, Hirose S, et al. Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration. Jpn J Ophthalmol 2013;57:68-73
31. Hara R, Kawaji T, Inomata Y, et al. Photodynamic therapy alone versus combined with intravitreal bevacizumab for neovascular age-related macular degeneration without polypoidal choroidal vasculopathy in Japanese patients. Graefes Arch Clin Exp Ophthalmol 2010;248:931-6
32. Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 2014;157:9-25
33. Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res 2012;31:495-525 • It is important because explain pathogenesis of myopic choroidal neovascularization (CNV).
34. Introini U, Casalino G, Querques G, et al. Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye (Lond) 2012;26:976-82
35. Foster P, Jiang Y. Epidemiology of myopia. Eye (Lond) 2014;28:202-8
36. Guo X, Xiao X, Li S, et al. Nonsyndromic high myopia in a Chinese family mapped to MYP1: linkage confirmation and phenotypic characterization. Arch Ophthalmol 2010;128:1473-9
37. Ratnamala U, Lyle R, Rawal R, et al. Refinement of the X-linked nonsyndromic high-grade myopia locus MYP1 on Xq28 and exclusion of 13 known positional candidate genes by direct sequencing. Invest Ophthalmol Vis Sci 2011;52:6814-19
38. Inhoffen W, Ziemssen F. [Morphological features of myopic choroidal neovascularization: differences to neovascular age-related macular degeneration]. Ophthalmologe 2012;109:749-57
39. Leveziel N, Caillaux V, Bastuji-Garin S, et al. Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization. Am J Ophthalmol 2013;155:913-19
40. Zhu Y, Zhang T, Xu G, Peng L. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia (protocol). Cochrane Database Syst Rev 2014
41. Giansanti F, Virgili G, Donati MC, et al. Long-term results of photodynamic therapy for subfoveal choroidal neovascularization with pathologic myopia. Retina 2012;32:1547-52 • This reference is uptodate and more original.
42. Rinaldi M, Chiosi F, Dell'omo R, et al. Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study. Retina 2013;33:397-402
43. Kitagawa T, Yuzawa M. [Intravitreal pegaptanib sodium for myopic choroidal neovascularization: 1 year results of a prospective pilot study]. Nippon Ganka Gakkai Zasshi 2013;117:344-50
44. Kitagawa T, Yuzawa M. [Comparison of 1-year treatment outcome of intravitreal pegaptanib sodium versus bevacizumab for myopic choroidal neovascularization]. Nippon Ganka Gakkai Zasshi 2013;117:727-34
45. Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014;121:682-92
46. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005;89:e1-1
47. Milani P, Massacesi A, Ciaccia S, et al. Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in naïve myopic choroidal neovascularization. Clin Ophthalmol 2011;6:1885-94
48. Gharbiya M, Cruciani F, Parisi F, et al. Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2012;96:1068-72
49. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 2010;248:937-41
50. Parodi MB, Iacono P, Papayannis A, et al. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia. Retina 2013;33:593-7
51. Chen CH, Wu PC, Chen YJ, et al. Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up. J Ocul Pharmacol Ther 2011;27:395-400
52. Ruiz-Moreno JM, Montero JA, Amat-Peral P. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses. Graefes Arch Clin Exp Ophthalmol 2011;249:595-9
53. Ruiz-Moreno JM, Montero JA, Arias L, et al. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization. Acta ophthalmol 2012;90:e82-3
54. Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010;128:437-42
55. Baba T, Kubota-Taniai M, Kitahashi M, et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010;94:864-70
56. Saviano S, Piermarocchi R, Leon PE, et al. Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study. Int J Ophthalmol 2014;7:335
57. Desco MC, Mataix J, Garcia-Pous M, et al. Combined therapy: photodynamic therapy and bevacizumab to treat myopic neovascular membranes. One-year follow-up. Retina 2011;31:475-81
58. Voykov B, Gelisken F, Inhoffen W, et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol 2010;248:543-50
59. Liang IC, Chang YY, Lee TS, et al. Treatment of myopic choroidal neovascularization with posterior sub-Tenon's bevacizumab injection (Avastin®). Int Ophthalmol 2014;34:971-7 •• Very important because they use bevacizumab in a new and better way for myopic CNV patients.
60. Ehlken C, Jungmann S, Bohringer D, et al. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond) 2014;28:538-45
61. Joussen AM, Bornfeld N. The treatment of wet age-related macular degeneration. Dtsch Arztebl Int 2009;65:3
62. Costagliola C, Agnifili L, Arcidiacono B, et al. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration. Expert Opin Biol Ther 2012;12:1299-313
63. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:C1375-86
64. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013;27:787-94
65. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98 •• They analyse the safety and efficacy of bevacizumab and ranibizumab and compared this two drugs.
66. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411 •• They analyse the safety and efficacy of bevacizumab and ranibizumab and compared this two drugs.
67. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-9
68. Zhang XY, Guo XF, Zhang SD, et al. Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. Int J Ophthalmol 2014;7:355-64
69. Kaiser PK, Cruess AF, Bogaert P, et al. Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 2012;250:1563-71
70. Thulliez M, Angoulvant D, Le Lez ML, et al. Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 2014. [Epub ahead of print]
71. Abdollahi M, Shafiee A, Bathaiee FS, et al. Drug-induced toxic reactions in the eye: an overview. J Infus Nurs 2004;2:386-98
72. Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014;42(1):D1091-7
73. Iwata E, Ueno S, Ishikawa K, et al. Focal macular electroretinograms after intravitreal injections of bevacizumab for age-related macular degeneration. Invest Ophthalmol Vis Sci 2012;53:4185-90
74. Tao Y, Libondi T, Jonas JB. Long-term follow-up after multiple intravitreal bevacizumab injections for exudative agerelated macular degeneration. J Ocul Pharmacol Ther 2010;26:79-84
75. Coppens G, Angulo Bocco M, Spielberg L, Leys A. Intravitreal bevacizumab for myopic choroidal neovascularization: 1-year and 2-year results. Bull Soc Belge Ophtalmol 2010;315:39-45
76. Peiretti E, Vinci M, Fossarello M. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results. Can J Ophthalmol 2012;47:28-33
77. Ruiz-Moreno JM, Montero JA, Arias L, et al. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization. Retina 2010;30:1609-15
78. Loh BK, Lee SY, Cheng J, et al. Intravitreal bevacizumab for the treatment of myopic choroidal neovascularisation in an Asian population. Ann Acad Med Singapore 2010;39:493
79. Iacono P, Parodi MB, Papayannis A, et al. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Retina 2011;31:1841-7
80. Nakanishi H, Tsujikawa A, Yodoi Y, et al. Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization. Eye (Lond) 2011;25:375-81